Gantenerumab arm of the phase II/III DIAN-TU-001 study did not meet its primary endpoint for early- onset Alzheimer's disease.- Roche
Related news and insights
Biogen Inc.has announced topline results from its Phase II TANGO study of gosuranemab (BIIB 092), an investigational anti-tau antibody that was being evaluated as a potential treatment for Alzheimer’s disease.
Cassava Sciences, Inc.has announced the initiation of a Cognition Maintenance Study (CMS) to evaluate simufilam in patients with Alzheimer’s disease. Simufilam is a drug candidate that seeks to reduce neurodegeneration and neuroinflammation.
Eisai Co., Ltd. and Biogen Inc. announced the publication of an article," A Randomized, Double-Blind Phase IIb Proof of Concept Clinical Trial in Early Alzheimer’s Disease with Lecanemab, an Anti-A? Protofibril Antibody", in the peer-reviewed journal Alzheimer’s Research and Therapy.